

**Special isirv-AVG Virtual Conference on
'Therapeutics for COVID-19'**

Tuesday 6th - Thursday 8th October 2020 (12.00-16.00 GMT daily)

Programme

Tuesday 6 October	
12:00-12:05	Welcome Alan Hay, Francis Crick Institute, London, UK & Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA
12:05-12:20	Opening Remarks <i>Jeremy Farrar, Wellcome Trust, London, UK</i>
12:20-14:05	Session 1 (Plenary) Co-Chairs: Bin Cao, China-Japan Friendship Hospital, Beijing, China & Maria Zambon, PHE, London, UK
12:20-12:45	COVID-19 Clinical Spectrum, Complications and Coinfections <i>Bin Cao, China-Japan Friendship Hospital, Beijing, China</i>
12:45-13:05	Viral Replication Kinetics and Antibody Responses <i>Malik Peiris, University of Hong Kong, HK SAR, China</i>
13:05-13:25	COVID-19 Autopsy Findings <i>Xiuwu Bian, Third Military Medical University, Chongqing, China</i>
13:25-13:45	Immunopathogenesis of COVID-19 <i>Peter Openshaw, Imperial College London, UK</i>
13:45-14:05	Pathogenesis and Management of ARDS – <i>Richard Wunderink, Northwestern University, Evanston, IL, USA</i>
14:05-14:15	Comfort Break

Tuesday 6 October	Continued..
14:15-15:50	Session 2 (Oral Abstract Session 1) Co-Chairs: John Beigel, NIAID, Bethesda, MD, USA & Alan Hay, Francis Crick Institute, London, UK
14:20-14:35	Sofosbuvir and Daclatasvir Compared to Standard of Care in the Treatment of Patients with Coronavirus Infection (COVID-19): A Randomised Controlled Trial - <i>Andrew Hill, University of Liverpool, Liverpool, UK</i>
14:35-14:50	Inhibition of Sirtuins is broadly effective against coronaviruses <i>Liudi Tang, Evrys Bio, LLC, Doylestown, PA, USA</i>
14:50-15:05	Safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, pilot trial - <i>Tom Wilkinson, University of Southampton, Southampton, UK</i>
15.05-15.20	Repurposing of clinically-approved drugs for the treatment of COVID-19 - <i>Kris White, Icahn School of Medicine at Mount Sinai, New York, NY, USA</i>
15.20-15.35	Safety and Tolerability of Lanadelumab, a Plasma Kallikrein Inhibitor, in Subjects Hospitalized With COVID-19-Related Pneumonia: Phase 1b Study Design - <i>Dan Sexton, Takeda Pharmaceutical Company Ltd, Lexington, MA, USA</i>
15.35-15.50	Fluvoxamine for prevention of clinical deterioration in early COVID-19: results from a randomized placebo-controlled trial <i>Angela M Reiersen, Washington University School of Medicine, St. Louis, MO, USA</i>
15:50-15:55	Close of Day 1
	Poster Viewing

Wednesday 7 October	
<p>12:00-13:50</p> <p>12:05-12:25</p> <p>12:25-12:45</p> <p>12:45-13:05</p> <p>13:05-13:25</p> <p>13:25-13:50</p>	<p>Session 3 (Plenary)</p> <p>Co-Chairs: Michael Ison, Northwestern University, Evanston, IL, USA & Hui-Ling Yen, University of Hong Kong, HK SAR, China</p> <p>SARS-CoV-2 Antiviral Targets <i>Mark Denison, Vanderbilt University Medical Center, Nashville, TN, USA</i></p> <p>Pre-clinical Models for Downselecting Candidates <i>Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France</i></p> <p>Convalescent Plasma and Polyclonal Antibodies <i>Michael Joyner, Mayo Clinic, Rochester, MN, USA</i></p> <p>Monoclonal Antibodies <i>Erica Saphire, La Jolla Institute for Immunology, CA, USA</i></p> <p>RECOVERY Trial and Strategies for Rapid Clinical Testing <i>Peter Horby, University of Oxford, Oxford, UK</i></p>
<p>13:50-14:00</p>	<p>Comfort Break</p>
<p>14:00-15:35</p> <p>14:05-14:20</p> <p>14:20-14:35</p> <p>14:35-14:50</p>	<p>Session 4 (Oral Abstract Session 2)</p> <p>Co-Chairs: Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France & Erica Saphire, La Jolla Institute for Immunology, CA, USA</p> <p>Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain That Escape Antibody Recognition - <i>Allison Greaney, Fred Hutchinson Cancer Research Center, Seattle, WA, USA</i></p> <p>Blockage of Cathepsin L Activity by SLV213, a Novel Cysteine Protease Inhibitor, Prevents SARS-CoV-2 Viral Entry <i>Felix Frueh, Selva Therapeutics, San Diego, CA, USA</i></p> <p>Effect of JAK inhibitor treatment on clinical outcome, lung pathology, and viral load in a mouse model of pathogenic SARS-CoV-2 infection - <i>Victoria Baxter, University of North Carolina at Chapel Hill, NC, USA</i></p>

<p>14:50-15:05</p>	<p>Treatment of Severe COVID-19 with Low-Dose Selnexor: Demonstration of Anti-Viral and Anti-Inflammatory Activities in a Randomized, International, Multicenter, Placebo-Controlled Phase 2 Clinical Trial - <i>George Geils, Roper St Francis Healthcare, Charleston, SC, USA</i></p>
<p>15:05-15:20</p>	<p>Marginal effect of GC-376 as a SARS-CoV-2 antiviral in the K18 hACE2 transgenic Mouse Model - <i>C. Joaquin Caceres, University of Georgia, Athens, Georgia, USA</i></p>
<p>15:20-15:35</p>	<p>A Phase 2 Study of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19) - <i>Harish Seethamraju, Montefiore Medical Center, Bronx, NY, USA</i></p>
<p>15:35-15:40</p>	<p>Close of Day 2</p>
	<p>Poster Viewing</p>

Thursday 8 October	
12:00-12:45	Session 5 (Plenary) Co-Chairs: Kim Armstrong, BARDA, Washington DC, USA & Frederick Hayden, , University of Virginia School of Medicine, Charlottesville, VA, USA
12:00-12:20	Lessons from MERS – <i>Yaseen Arabi, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia</i>
12:20-12:45	Solidarity Trial & Lessons Learned <i>Marie-Pierre Preziosi, WHO, Geneva, Switzerland</i>
12:45-14:10	Session 6 (Clinical Trials Updates) Co-Chairs: Kim Armstrong, BARDA, Washington DC, USA & Frederick Hayden, , University of Virginia School of Medicine, Charlottesville, VA, USA
12:45-12:50	Introduction
12:50-13:05	Remdesivir - <i>Anu Osinusi, Gilead, Foster City, CA, USA</i>
13:05-13:20	EIDD-2801 - <i>Wendy Painter, Ridgeback Biotherapeutics LP, Miami, FL, USA</i>
13:20-13:35	Favipirivir – <i>Yohei Doi, University of Pittsburgh, PA, USA</i>
13:35-13:50	JAK Inhibitors - <i>John Beigel, NIAID, Bethesda, MD, USA</i>
13:50-14:05	Tocilizumab – <i>Larry Tsai, Genentech, S. San Francisco, CA, USA</i>
14:05-14:10	Summary
14:10-14:20	Comfort Break
14:20-15:30	Session 7 (Plenary) Co-Chairs: Michael Ison, Northwestern University, Evanston, IL, USA & Marco Cavaleri, European Medicines Agency, Amsterdam, Netherlands
14:20-14:45	Operation Warp Speed Therapeutics Development <i>Janet Woodcock, CDER, FDA, Washington DC, USA</i>
14:45-15:05	Discussion on Clinical Trial Endpoints – <i>moderated by Michael Ison, Northwestern University, Evanston, IL, USA & Marco Cavaleri, European Medicines Agency, Amsterdam, Netherlands</i>
15:05-15:30	WHO Update on COVID-19 Clinical Management <i>Janet Diaz, WHO, Geneva, Switzerland</i>
15:30-15:45	Close of Conference